Aptevo reports 89% remission in frontline AML with mipletamig; Q3 net loss $7.5M

Aptevo Therapeutics Inc.

2025-Q3 EPS reported -$11.42

89% of evaluable frontline AML patients achieved remission (CR+CRi) across two trials of mipletamig; no cytokine release syndrome observed.
Introduced trispecific molecules APVO451 and APVO452 for solid tumors, expanding CD3 T-cell engager portfolio to five candidates.
Raised $18.7M net in Q3 and additional $4.1M in October; proforma cash $25.2M extends runway into 4Q26.
Q3 net loss $7.5M ($2.23 per share) vs $5.1M ($357.86 per share) in Q3 2024; R&D spend $4.0M, G&A $3.6M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.